ZSAN Zosano Pharma Corporation

1.77
+0  (4%)
Previous Close 1.70
Open 1.79
Price To book 6.37
Market Cap 34.43M
Shares 19,450,000
Volume 3,823,411
Short Ratio 0.15
Av. Daily Volume 3,448,760

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial data due released February 13, 2017 - primary endpoints met.
M207
Migraine
Phase 2 data released September 2015. Considering Phase 3 initiation in 2016
ZP-Glucagon
Severe hypoglycemia

Latest News

  1. Zosano Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Over-Allotment Option
  2. Zosano Announces Pricing of Public Offering of Common Stock
  3. ZOSANO PHARMA CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  4. ZOSANO PHARMA CORP Financials
  5. Penny Stocks to Watch for March 2017 (MOBL)
  6. ZOSANO PHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
  7. Zosano Pharma Reports Fourth Quarter and Fiscal 2016 Financial Results and Business Update
  8. ZOSANO PHARMA CORP Files SEC form 10-K, Annual Report
  9. Biotech Industry Shaping up to Have a Breakout Year in 2017: Today's Reports on Insys Therapeutics and Zosano Pharma
  10. Zosano Pharma Corp (ZSAN) Is Playing With The Big Boys In The Migraine Space
  11. ZOSANO PHARMA CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  12. Can Zosano Pharma Turn Itself Around With This Late-Stage Migraine Trial Win?
  13. Fear of Missing Out Is Building
  14. Zosana Pharma's stock rockets after migraine patch produces positive trial results
  15. Zosano Pharma Announces 3.8mg Dose of M207, its Novel Transdermal Therapeutic, Meets Both Co-primary Endpoints in the ZOTRIP Pivotal Efficacy Trial in Migraine
  16. ZOSANO PHARMA CORP Files SEC form 8-K, Other Events
  17. Zosano Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
  18. Zosano Pharma Announces Last Subject Treated in its Migraine Pivotal Trial
  19. Zosano Pharma Announces Last Subject Treated in its Migraine Pivotal Trial
  20. Zosano Pharma Announces Sale of Non-Strategic Asset